PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UK researchers make new Alzheimer’s disease discovery

Researchers at the Universities of St Andrews and Edinburgh say they have discovered the functions of the area of the brain in which Alzheimer’s begins, potentially opening the door to new approaches to treatment the disease.

Alzheimer’s is the most common form of dementia, with more than 520,000 people in the UK suffering from the disorder.

The first symptoms are related to episodic memory, with patients experiencing difficulty remembering the things that have happened to them.

The new research, published in Current Biology, focused on one of the first brain areas to show changes in Alzheimer’s – the lateral entorhinal cortex (LEC).

This consists of layers of cells which form complex networks of connections with other brain regions and contains sub-systems that have different memory functions.

The team, led by Dr Brianna Vandrey now of Edinburgh University, found that when a particular connection between one of the layers of the LEC and the hippocampus malfunctions, episodic memory is affected while simpler forms of memory remain unaffected.

“This research is important as it gives us a very specific target when developing treatments and strategies to prevent neurodegeneration in Alzheimer’s disease,” said Dr James Ainge of the School of Psychology and Neuroscience at the University of St Andrews, commenting on the findings.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026